In the Media

Viewing records where tag name contains "media" View All

Which ASX companies are resurrecting abandoned drugs? Part 3

Apr 18th, 2024

"SPL has developed its proprietary Dendrimer Enhanced Products platform (DEP) to improve the effectiveness and safety of drugs, especially cancer treatments." Read the full article in Stockhead. 

Read More

Which ASX companies are resurrecting abandoned drugs? Part 3

Apr 18th, 2024

DEP is based on dendrimers, which are highly branched polymers, to enhance the delivery of cancer treatments and reduce toxic side effects such as neutropenia, nausea, severe diarrhoea and hair loss from chemotherapy agents. Read the full article in The Australian Business Review. 

Read More

Breaking new ground via an oncology treatment tech venture

Apr 9th, 2024

Cheryl Maley, CEO of Starpharma (SPL), provides insight into the partnreship with Medicxi, materialising in Petalion Therapeutics in the UK. 

Read More

Aussie tech behind new company

Apr 9th, 2024

Starpharma's partnership with Medicxi was featured in Pharma In Focus.

Read More

Australia's Starpharma and UK-based Medicxi create Petalion Therapeutics to develop novel dendrimer-based treatments

Apr 9th, 2024

Read the coverage of Starpharma's partnership with Medicxi in BioSpectrum Asia.

Read More

Starpharma and Medicxi to partner in Petalion Therapeutics, advancing dendrimer-drug cancer treatments

Apr 9th, 2024

"Australian biotech Starpharma Holdings (ASX: SPL) has entered into a strategic partnership with UK life sciences investment firm Medicxi to establish a UK-based company known as Petalion Therapeutics." 

Read More